Knowledge Ecology International

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading →

In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:

Continue Reading →

The Global Ministerial Forum on Research for Health is meeting in Bamako, Mali from November 17-19, 2008. This Ministerial is organized by the Council on Health Research for Development (COHRED), Global Forum for Health Research, the Republic of Mali, the United Nations Cultural, Scientific and Educational Organization (UNESCO), the World Bank and the World Health Organization (WHO), and coordinated by the Bamako 2008 Secretariat.

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.

Page 53-54

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.

Page 105-106

Medical Innovation Prize Act of 2007

Continue Reading →

In book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss why voluntary licensing of patents is not required.

Page 22

Voluntary Licensing

Continue Reading →

Aidan Hollis and Thomas Pogge discuss Intellectual Property and the HIF.*

Intellectual Property

Continue Reading →

KEI will later issue a more detailed comment on the Health Impact Fund. One of the key issues that will be addressed is the way that Hollis and Pogge propose turning the prize fund proposals that are based upon open licensing of patents into something that reinforces the monopoly supply chain.

We understand that one motivation for doing this was to attract support from some large pharmaceutical companies, and the European governments that protect them.

Continue Reading →

WHO has announced the names for the Expert Working Group on R&D financing

We don’t know everyone on the list, but for the people that we do know, we are generally impressed. The WHO seems to have created a body with considerable expertise and reputation, and included people who will consider new ideas. This seems like a very good start.

http://www.who.int/phi/R_Dfinancing/en/index.html

Continue Reading →